Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research> UBS Raises Shanghai Pharmaceuticals (02607.HK) TP to HKD15.2, Rating 'Buy'
Recommend 1 Positive 3 Negative 1 |
||||
|
||||
|
UBS released a research report stating that Shanghai Pharmaceuticals (02607.HK) saw a 3% year-on-year increase in total revenue to RMB284 billion last year, with net profit rising 25.7% year-on-year to RMB5.72 billion. However, recurring net profit fell 26.7% year-on-year to RMB2.98 billion, roughly in line with expectations. The firm noted that considering Shanghai Pharmaceuticals' strategic positioning, diversified business, and competitive advantage in rapidly growing sectors, it expects the company's growth during the '14th Five-Year Plan' period to surpass its peers in pharmaceutical distribution. UBS adjusted its earnings forecast for Shanghai Pharmaceuticals from 2026 to 2028 by decreasing it by 1% to increasing it by 3%. The target price was raised from HKD15 to HKD15.2, with a 'Buy' rating. (ca/j) Auto-translated by third-party software This translation was auto-generated by third-party software. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. |
||||
Copied to Clipboard
 |
||||
